Advertisement
Document › Details
Roche. (11/17/17). "Press Release: Roche to Acquire Viewics, Inc. to Provide Data-driven Lab Business Analytics and Add further Digital Capabilities along the Laboratory Value Chain". Basel.
Organisation | Roche Diagnostics (Group Division) | |
Group | Roche (Group) | |
Organisation 2 | Viewics Inc. | |
Group | Roche (Group) | |
Product | data analysis s/w (general) | |
Product 2 | laboratory equipment management services | |
Index term | Viewics–Roche: investment, 201711 acquisition of Viewics Inc by Roche | |
Person | Diggelmann, Roland (Roche 201209–201809 CEO of Roche Diagnostics before Head Asia-Pacific LEFT 9/18) | |
Person 2 | Bhatia, Dhiren (Viewics 201711 President + Founder) | |
> The Viewics solution allows for efficient integration of big data from a variety of IT systems in the laboratory and beyond, pioneering a new way in extracting, cleansing, transforming and augmenting data.
> Executive, financial, operational, technical, and laboratory roles gain comprehensive insights, enabling data-driven decisions that improve laboratory processes and performance.
> Viewics, Inc. will become an integral part of Roche and add further digital capabilities on top of Roche Diagnostics’ Integrated Core Lab offering.
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced an agreement with Viewics, Inc., a privately held software company focused on laboratory business analytics. Under the agreement, Roche is acquiring all shares of the company. The acquisition, which is subject to customary closing conditions, is expected to close on November 21, 2017. This acquisition allows Roche to expand its leading position in the Integrated Core Lab with business analytics capabilities, enabling laboratories to make faster data-driven informed decisions on their operations and processes. The cloud-based solution is secure, infrastructure-agnostic, interactive, and accessible from multiple devices (e.g. smart phones, tablets, desktop computers).
“We are excited that Viewics, Inc. will be joining the Roche Group, as it will help us to support our customers around the world in improving their lab performance and processes,” said Roland Diggelmann, CEO Roche Diagnostics. “The Viewics solution offers our customers insights at their fingertips, uncovering potential value and profitability drivers in lab operations, and indicators to improve overall quality of care”.
“We founded Viewics with the belief that unlocking the value of data would drive immense value for our customers. With Roche’s expertise and strong alignment within our teams, we are excited to embark on this next phase of Viewics’ journey and jointly deliver on this mission,” said Dhiren Bhatia, Founder and President of Viewics, Inc.
“Viewics, Inc. strives to provide unprecedented access to disparate healthcare data to surface actionable insights and empower data-driven decision-making,” said Keith Laughman, CEO of Viewics, Inc. “The Viewics platform generates insights that can inform real-time decisions about costs, laboratory performance, and many other areas affecting today’s modern healthcare organizations. We are looking forward to working with our Roche colleagues in helping to support the lab’s critical role in healthcare delivery.
The Viewics solution offers automated data extraction, cleansing, and augmentation architecture and resolves many of the typical problems that laboratory IT staff encounter when using generic business intelligence solutions, traditional data warehousing, or extraction methodologies.
About Viewics, Inc.
Viewics, Inc. was founded in 2010 in Sunnyvale, CA (USA) and is an established market player in business analytics for laboratories. The company, headquartered in San Jose, CA, has employees across the U.S. and in its subsidiary in Pune, India.
Through expertise and focus on healthcare analytics, Viewics, Inc. delivers proprietary, best-in-class technology for data extraction, cleansing, and transformation that quickly unlock insights, which deliver invaluable operational and financial outcomes, while reducing burden on IT.
The HIPAA-compliant solution puts the transformational power of analytics into the hands of healthcare professionals in laboratory, financial, executive, and IT roles. The solution enables organizations to leverage insights out-of-the-box, combined with the flexibility of further customising the solution to meet the needs of their unique situations, truly interact with their data and make decisions based on accurate information to deliver significant impact.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
Record changed: 2023-06-05 |
Advertisement
More documents for Roche (Group)
- [1] Pfizer Inc.. (4/26/24). "Press Release: U.S. FDA Approves Pfizer’s Beqvez (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B". New York, NY....
- [2] Roche. (4/11/24). "Press Release: Roche Granted FDA Breakthrough Device Designation for Blood Test to Support Earlier Alzheimer's Disease Diagnosis". Basel....
- [3] Freenome, Inc.. (2/15/24). "Press Release: Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection". South San Francisco, CA....
- [4] PathAI Inc.. (2/13/24). "Press Release: PathAI Announces Exclusive Collaboration with Roche Tissue Diagnostics to Advance AI-enabled Interpretation for Companion Diagnostics". Boston, MA....
- [5] Repare Therapeutics Inc.. (2/12/24). "Press Release: Repare Therapeutics to Regain Global Rights to Camonsertib". Cambridge, MA & Montréal....
- [6] Hookipa Pharma Inc.. (1/29/24). "Press Release: Hookipa Pharma Provides Update on Business Priorities and Oncology Partnership Programs". New York, NY & Vienna....
- [7] Repare Therapeutics Inc.. (1/25/24). "Press Release: Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment". Cambridge, MA & Montréal....
- [8] Remix Therapeutics, Inc.. (1/3/24). "Press Release: Remix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing". Watertown, MA....
- [9] MediLink Therapeutics (Suzhou) Co., Ltd.. (1/2/24). "Press Release: MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to Develop Next-generation Antibody Drug Conjugate in Oncology". Suzhou....
- [10] Roche. (12/29/23). "Press Release: Roche Enters into a Definitive Agreement to Acquire LumiraDx's Point of Care Technology Combining Multiple Diagnostic Modalities on a Single Platform". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top